Fig. 7From: Cardiovascular and microvascular outcomes of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled cardiovascular outcome trials with trial sequential analysisEffects of GLP1R agonists on HbA1c, body weight, systolic blood pressure and heart rate. CI, confidence interval; GLP1R, glucagon-like peptide–1 receptor; WMD, weighted mean differenceBack to article page